New research reveals that intermittent fasting can significantly enhance the effectiveness of oestrogen-blocking breast ...

In premenopausal women with non-metastatic breast cancer, use of tamoxifen may nearly double the risk of endometrial cancer, researchers report.

As of Thursday, December 11, Atossa Therapeutics, Inc.’s ATOS share price has surged by 9.41%, which has investors ...

In an international study led by UCLA, researchers have shown that giredestrant, a next-generation oral selective estrogen ...

In an international study led by UCLA, researchers have shown that giredestrant, a next-generation oral selective estrogen ...

Among more than 4,000 patients with hormone receptor (HR)-positive disease, 3-year invasive disease-free survival (IDFS) ...

Roche has lifted the lid on the data behind its second phase 3 giredestrant win, linking the oral selective estrogen receptor ...

Adjuvant giredestrant significantly improved invasive DFS vs. standard-of-care endocrine therapy in patients with early-stage ...

The investigational, oral selective estrogen receptor degrader (SERD) giredestrant  given as an adjuvant therapy showed significant improvement in invasive disease-free survival (iDFS) compared with ...

Giredestrant significantly improved IDFS over SOC endocrine therapy, reducing the risk of invasive disease recurrence or ...